when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

daraxonrasib · news · pharmadog

← back to daraxonrasib

News mentioning daraxonrasib

43 stories

10hRevolution drug heralded as a pancreatic cancer breakthrough cleared by FDAbiopharma dive

12hRevMed receives early FDA approval for ‘groundbreaking’ pancreatic cancer drugbiospace

12hFDA approves Revolution Medicines' pancreatic cancer drugendpoints

12hSTAT+: FDA approves new pancreatic cancer drug expected to usher in new era of treatmentstat

13hFDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancerfda press

16hFDA greenlights Revolution Medicines' pancreatic cancer gamechangerfiercebiotech

17hAkeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debatefiercebiotech

19d‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culpritbiopharma dive

21dRevolution Medicines preps for launching pancreatic cancer drug, ups 2026 expensesendpoints

Jul 24, 26Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myelomabiopharma dive

Jul 23, 26FDA panel confronting peptide controversystat

Jul 17, 26BlossomHill eyes IPO as fertilizer to grow taller in crowded cancer fieldsfiercebiotech

Jul 13, 26STAT+: All eyes on data on Biogen’s tau therapystat

Jul 13, 26Caregivers brace for pay cuts, and maybe homelessnessstat

Jul 13, 26STAT+: A breakthrough in pancreatic cancer has experts excited — and braced for what’s to comestat

Jul 8, 26Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversalbiopharma dive

Jun 26, 26FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences servicesbiopharma dive

Jun 19, 26Opinion: STAT+: The real work for making dramatic gains against pancreatic cancer is just beginningstat

Jun 8, 26Tango data add to growing momentum for pancreatic cancer drugsbiopharma dive

Jun 8, 26Tango plans Phase 3 pancreatic cancer study after combo successendpoints

Jun 8, 26STAT+: Pharmalittle: We’re reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and morestat

Jun 8, 26STAT+: Combination of pancreatic cancer drugs from Tango, Revolution leads to high response ratestat

Jun 5, 26STAT+: Will Makary’s FDA voucher program survive?stat

Jun 4, 26What RevMed’s pancreatic cancer drug meant for one patientstat

Jun 4, 26STAT+: For pancreatic cancer patients, an exciting drug can feel out of reachstat

Jun 4, 26STAT+: Does Revolution Medicines’ pancreatic cancer drug have even greater potential?stat

Jun 1, 26STAT+: At ASCO, talk of barriers to cancer care, new treatments, and other big takeawaysstat

Jun 1, 26STAT+: Pharmalittle: We’re reading about pancreatic and lung cancer drugs, China biotech growth, and morestat

Jun 1, 26STAT+: A turning point for pancreatic cancer patientsstat

May 31, 26STAT+: Practice-changing results reported for Revolution Medicines pancreatic cancer drugstat

← prevpage 1 of 2next →